Table II.
AmoyDX HRD testing results according to clinicopathological characteristics.
| Clinico-pathological feature | HRD Positive (n = 38) | HRD Negative (n = 42) | p value | |
|---|---|---|---|---|
| Age at diagnosis median (range) | 59.5 (36-79) | 64 (43-82) | 0.03* | |
| Histotype | ||||
| HGSOC | 38 (100%) | 40 (95.2%) | ||
| HGEOC | 0 | 1 (2.4%) | 0.99 | |
| MMMT | 0 | 1 (2.4%) | ||
| Family history | ||||
| Positive | 26 (68.4%) | 21 (50%) | 0.09 | |
| Negative | 12 (31.6%) | 21 (50%) | ||
| tBRCA status | ||||
| Positive | 4 (10.5%) | 1 (2.4%) | 0.13 | |
| Negative | 34 (89.5%) | 41 (97.6%) | ||
* p value statistically significant.
HGSOC: High grade serous carcinoma; HGEOC: High grade endometrioid carcinoma; MMMT: Malignant mixed Mullerian tumor; tBRCA = tumor BRCA.